EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are the standard of care for non-small cell lung cancer (NSCLC) patients with <i>EGFR</i> exon 19 deletion and L858R mutations.